Find a Trial
Trial Summary
| Protocol No. | PHO-NOVARTIS-CCTL019G2201J | ||
|---|---|---|---|
| Status | OPEN TO ACCRUAL | ||
| Principal Investigator | Rahrig, April | ||
| Scope | National | ||
| Phase | Phase II | ||
| Age Group | Children | ||
| Title | A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy | ||
| Applicable Disease Sites | Leukemia, other | ||
| Participating Institutions | Indiana University (IU) | ||
| Treatment Type | Treatment | ||
| Contact | Courtney B. Spiegel, | Phone: +1 317-948-0581 Pager: Email: clorch@iu.edu | |